Published on 1 Mar 2024 on Zacks via Yahoo Finance
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat
Mirum Pharmaceuticals, Inc. MIRM reported a fourth-quarter 2023 loss of 66 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents. The company reported a loss of 99 cents per share in the year-ago quarter.
Revenues in the fourth quarter totaled $69.6 million, up 149.2% year over year. The figure also beat the Zacks Consensus Estimate of $67 million. The top line comprised Livmarli sales and newly acquired Cholbam and Chenodal sales.
Mirum acquired Travere Therapeutics’ bile acid products in August 2023, which added the latter’s Cholbam capsules and Chenodal tablets to its portfolio of commercialized drugs.